Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Antimicrobial treatment challenges in the era of carbapenem resistance.

Peri AM, Doi Y, Potoski BA, Harris PNA, Paterson DL, Righi E.

Diagn Microbiol Infect Dis. 2019 Aug;94(4):413-425. doi: 10.1016/j.diagmicrobio.2019.01.020. Epub 2019 Feb 5. Review.

PMID:
30905487
2.

Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.

Haidar G, Philips NJ, Shields RK, Snyder D, Cheng S, Potoski BA, Doi Y, Hao B, Press EG, Cooper VS, Clancy CJ, Nguyen MH.

Clin Infect Dis. 2017 Jul 1;65(1):110-120. doi: 10.1093/cid/cix182.

3.

Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.

Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV, Doi Y, Kreiswirth BN, Clancy CJ.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00883-17. doi: 10.1128/AAC.00883-17. Print 2017 Aug.

4.

Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure.

Buehrle DJ, Shields RK, Clarke LG, Potoski BA, Clancy CJ, Nguyen MH.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01243-16. doi: 10.1128/AAC.01243-16. Print 2017 Jan.

5.

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.

Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, Press EG, Kreiswirth BN, Clancy CJ, Nguyen MH.

Clin Infect Dis. 2016 Dec 15;63(12):1615-1618. Epub 2016 Sep 13.

6.

Dosing Practices of Intravenous Acyclovir for Herpes Encephalitis in Obesity: Results of a Pharmacist Survey.

Wong A, Pickering AJ, Potoski BA.

J Pharm Pract. 2017 Jun;30(3):324-328. doi: 10.1177/0897190016642689. Epub 2016 Apr 10.

PMID:
27067742
7.

Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.

Buehrle DJ, Shields RK, Chen L, Hao B, Press EG, Alkrouk A, Potoski BA, Kreiswirth BN, Clancy CJ, Nguyen MH.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3227-31. doi: 10.1128/AAC.02969-15. Print 2016 May.

8.

Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia.

Shields RK, Nguyen MH, Potoski BA, Press EG, Chen L, Kreiswirth BN, Clarke LG, Eschenauer GA, Clancy CJ.

Antimicrob Agents Chemother. 2015 Mar;59(3):1797-801. doi: 10.1128/AAC.03894-14. Epub 2014 Dec 22.

9.

Calming the "perfect storm" in methicillin-resistant Staphylococcus aureus bacteremia: a call for a more balanced discussion.

Eschenauer GA, Nagel JL, Kubin CJ, Lam SW, Patel TS, Potoski BA.

Clin Infect Dis. 2015 Feb 15;60(4):670-1. doi: 10.1093/cid/ciu883. Epub 2014 Nov 3. No abstract available.

PMID:
25371485
10.

Targeted versus universal antifungal prophylaxis among liver transplant recipients.

Eschenauer GA, Kwak EJ, Humar A, Potoski BA, Clarke LG, Shields RK, Abdel-Massih R, Silveira FP, Vergidis P, Clancy CJ, Nguyen MH.

Am J Transplant. 2015 Jan;15(1):180-9. doi: 10.1111/ajt.12993. Epub 2014 Oct 30.

11.

Bringing the "power" to Cerner's PowerChart for antimicrobial stewardship.

Pogue JM, Potoski BA, Postelnick M, Mynatt RP, Trupiano DP, Eschenauer GA, Kaye KS.

Clin Infect Dis. 2014 Aug 1;59(3):416-24. doi: 10.1093/cid/ciu271. Epub 2014 Apr 18.

PMID:
24748518
12.

Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates.

Eschenauer GA, Nguyen MH, Shoham S, Vazquez JA, Morris AJ, Pasculle WA, Kubin CJ, Klinker KP, Carver PL, Hanson KE, Chen S, Lam SW, Potoski BA, Clarke LG, Shields RK, Clancy CJ.

Antimicrob Agents Chemother. 2014;58(4):1897-906. doi: 10.1128/AAC.02163-13. Epub 2014 Jan 6.

13.

Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection.

Casapao AM, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, LaPlante KL, Potoski BA, Rybak MJ.

Antimicrob Agents Chemother. 2013 Sep;57(9):4252-4259. doi: 10.1128/AAC.00380-13. Epub 2013 Jun 24.

14.

Multicenter study of high-dose daptomycin for treatment of enterococcal infections.

Casapao AM, Kullar R, Davis SL, Levine DP, Zhao JJ, Potoski BA, Goff DA, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ.

Antimicrob Agents Chemother. 2013 Sep;57(9):4190-6. doi: 10.1128/AAC.00526-13. Epub 2013 Jun 17.

15.

Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients.

Shields RK, Clancy CJ, Gillis LM, Kwak EJ, Silveira FP, Massih RC, Eschenauer GA, Potoski BA, Nguyen MH.

PLoS One. 2012;7(12):e52349. doi: 10.1371/journal.pone.0052349. Epub 2012 Dec 20.

16.

Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study.

Eschenauer GA, Carver PL, Lin SW, Klinker KP, Chen YC, Potoski BA, Shields RK, Clancy CJ, Nguyen MH, Lam SW.

J Antimicrob Chemother. 2013 Apr;68(4):922-6. doi: 10.1093/jac/dks482. Epub 2012 Dec 4.

17.

Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens.

Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y.

Antimicrob Agents Chemother. 2012 Apr;56(4):2108-13. doi: 10.1128/AAC.06268-11. Epub 2012 Jan 17.

18.

High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen.

Shields RK, Kwak EJ, Potoski BA, Doi Y, Adams-Haduch JM, Silviera FP, Toyoda Y, Pilewski JM, Crespo M, Pasculle AW, Clancy CJ, Nguyen MH.

Diagn Microbiol Infect Dis. 2011 Jun;70(2):246-52. doi: 10.1016/j.diagmicrobio.2010.12.023. Epub 2011 Feb 25.

PMID:
21353436
19.

Presence of adequate intravitreal concentrations of daptomycin after systemic intravenous administration in a patient with endogenous endophthalmitis.

Sheridan KR, Potoski BA, Shields RK, Nau GJ.

Pharmacotherapy. 2010 Dec;30(12):1247-51. doi: 10.1592/phco.30.12.1247.

PMID:
21114392
20.

Lactobacillus probiotic use in cardiothoracic transplant recipients: a link to invasive Lactobacillus infection?

Luong ML, Sareyyupoglu B, Nguyen MH, Silveira FP, Shields RK, Potoski BA, Pasculle WA, Clancy CJ, Toyoda Y.

Transpl Infect Dis. 2010 Dec;12(6):561-4. doi: 10.1111/j.1399-3062.2010.00580.x. Epub 2010 Oct 7. Review.

PMID:
21040283
21.

Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients.

Han K, Capitano B, Bies R, Potoski BA, Husain S, Gilbert S, Paterson DL, McCurry K, Venkataramanan R.

Antimicrob Agents Chemother. 2010 Oct;54(10):4424-31. doi: 10.1128/AAC.00504-10. Epub 2010 Aug 2.

22.

Aminoglycoside use in intensive care units and aminoglycoside nephrotoxicity. Comment letter 1.

Pogue JM, Potoski BA, Kaye KS.

Antimicrob Agents Chemother. 2010 Jun;54(6):2750, author reply 2751. doi: 10.1128/AAC.00892-09. No abstract available.

23.

Interspecies spread of Klebsiella pneumoniae carbapenemase gene in a single patient.

Sidjabat HE, Silveira FP, Potoski BA, Abu-Elmagd KM, Adams-Haduch JM, Paterson DL, Doi Y.

Clin Infect Dis. 2009 Dec 1;49(11):1736-8. doi: 10.1086/648077.

PMID:
19886795
24.

Is vancomycin ototoxicity a significant risk?

Shields RK, Martello JL, Potoski BA.

Antimicrob Agents Chemother. 2009 Oct;53(10):4572; author reply 4572-3. doi: 10.1128/AAC.00537-09. No abstract available.

25.

Extensively drug-resistant Acinetobacter baumannii.

Doi Y, Husain S, Potoski BA, McCurry KR, Paterson DL.

Emerg Infect Dis. 2009 Jun;15(6):980-2. doi: 10.3201/eid1506.081006. No abstract available.

26.

Activity of temocillin against KPC-producing Klebsiella pneumoniae and Escherichia coli.

Adams-Haduch JM, Potoski BA, Sidjabat HE, Paterson DL, Doi Y.

Antimicrob Agents Chemother. 2009 Jun;53(6):2700-1. doi: 10.1128/AAC.00290-09. Epub 2009 Mar 30. No abstract available.

27.

Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients.

Johnson LE, D'Agata EM, Paterson DL, Clarke L, Qureshi ZA, Potoski BA, Peleg AY.

Transpl Infect Dis. 2009 Jun;11(3):227-34. doi: 10.1111/j.1399-3062.2009.00380.x. Epub 2009 Mar 2. Erratum in: Transpl Infect Dis. 2009 Aug;11(4):382.

PMID:
19302282
28.

Cefepime MIC breakpoint resettlement in gram-negative bacteria.

Chin BS, Seo WY, Paterson DL, Potoski BA, Peleg AY.

Antimicrob Agents Chemother. 2009 Jan;53(1):337-8. doi: 10.1128/AAC.00106-08. No abstract available.

29.

Simple disk-based method for detection of Klebsiella pneumoniae carbapenemase-type beta-lactamase by use of a boronic acid compound.

Doi Y, Potoski BA, Adams-Haduch JM, Sidjabat HE, Pasculle AW, Paterson DL.

J Clin Microbiol. 2008 Dec;46(12):4083-6. doi: 10.1128/JCM.01408-08. Epub 2008 Oct 15.

30.

Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania.

Adams-Haduch JM, Paterson DL, Sidjabat HE, Pasculle AW, Potoski BA, Muto CA, Harrison LH, Doi Y.

Antimicrob Agents Chemother. 2008 Nov;52(11):3837-43. doi: 10.1128/AAC.00570-08. Epub 2008 Aug 25.

31.

Acquisition of rectal colonization by vancomycin-resistant Enterococcus among intensive care unit patients treated with piperacillin-tazobactam versus those receiving cefepime-containing antibiotic regimens.

Paterson DL, Muto CA, Ndirangu M, Linden PK, Potoski BA, Capitano B, Bonomo RA, Aron DC, Donskey CJ.

Antimicrob Agents Chemother. 2008 Feb;52(2):465-9. Epub 2007 Nov 19.

32.

Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus.

Pogue JM, Paterson DL, Pasculle AW, Potoski BA.

Infect Control Hosp Epidemiol. 2007 Dec;28(12):1382-8. Epub 2007 Nov 1.

PMID:
17994519
33.

Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive "bundle" approach.

Muto CA, Blank MK, Marsh JW, Vergis EN, O'Leary MM, Shutt KA, Pasculle AW, Pokrywka M, Garcia JG, Posey K, Roberts TL, Potoski BA, Blank GE, Simmons RL, Veldkamp P, Harrison LH, Paterson DL.

Clin Infect Dis. 2007 Nov 15;45(10):1266-73. Epub 2007 Oct 9.

PMID:
17968819
34.

Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms.

Bhat SV, Peleg AY, Lodise TP Jr, Shutt KA, Capitano B, Potoski BA, Paterson DL.

Antimicrob Agents Chemother. 2007 Dec;51(12):4390-5. Epub 2007 Oct 15.

35.

Appropriate pharmacokinetic index for outcome in Staphylococcus aureus pneumonia.

Potoski BA, Paterson DL.

Chest. 2007 Sep;132(3):1101-2; author reply 1102-3. No abstract available.

PMID:
17873215
36.

Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved?

Bhat S, Fujitani S, Potoski BA, Capitano B, Linden PK, Shutt K, Paterson DL.

Int J Antimicrob Agents. 2007 Nov;30(5):458-62. Epub 2007 Aug 20.

PMID:
17703923
37.

Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report.

Peleg AY, Potoski BA, Rea R, Adams J, Sethi J, Capitano B, Husain S, Kwak EJ, Bhat SV, Paterson DL.

J Antimicrob Chemother. 2007 Jan;59(1):128-31. Epub 2006 Nov 1.

PMID:
17082201
38.

Epidemiological profile of linezolid-resistant coagulase-negative staphylococci.

Potoski BA, Adams J, Clarke L, Shutt K, Linden PK, Baxter C, Pasculle AW, Capitano B, Peleg AY, Szabo D, Paterson DL.

Clin Infect Dis. 2006 Jul 15;43(2):165-71. Epub 2006 Jun 5.

PMID:
16779742
39.

Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen.

Capitano B, Potoski BA, Husain S, Zhang S, Paterson DL, Studer SM, McCurry KR, Venkataramanan R.

Antimicrob Agents Chemother. 2006 May;50(5):1878-80.

40.

Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections.

Capitano B, Nicolau DP, Potoski BA, Byers KE, Horowitz M, Venkataramanan R, Paterson DL.

Pharmacotherapy. 2004 Jun;24(6):803-7.

PMID:
15222672
41.

Clinical failures of linezolid and implications for the clinical microbiology laboratory.

Potoski BA, Mangino JE, Goff DA.

Emerg Infect Dis. 2002 Dec;8(12):1519-20. No abstract available.

42.

The safety of voriconazole.

Potoski BA, Brown J.

Clin Infect Dis. 2002 Nov 15;35(10):1273-5. No abstract available.

PMID:
12410490

Supplemental Content

Loading ...
Support Center